OPRX news

Latest 1 stories · newest Nov 13, 2026

OPRX

OptimizeRx Q3 2026: Revenue Down But Profits Rise on Strong EBITDA Margins

OptimizeRx reported Q3 2026 revenue of $21.6M and adjusted EBITDA of $6.3M, significantly beating consensus. The company updated fiscal year 2026 revenue guidance to $87M-$93M, citing year-over-year contract declines offsetting RFP momentum. Debt reduction also continued.

Earnings|Guidance Nov 13, 2026 sentiment +0.20 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same OPRX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/OPRX/newsSTART FREE